Showing 1,681 - 1,700 results of 14,345 for search '"evidence"', query time: 0.08s Refine Results
  1. 1681

    Methods to appraise available evidence and adequacy of data from a systematic literature review to conduct a robust network meta-analysis of treatment options for patients with hospital-acquired or ventilator-associated bacterial pneumonia. by Laura Puzniak, Ryan Dillon, Thomas Lodise

    Published 2023-01-01
    “…We identified relevant RCTs for most standard-of-care agents approved for HABP/VABP, which provided a comprehensive evidence base. In summary, our appraisal of available evidence for the clinical response outcome among adult patients with HABP/VABP does not support the conduct of a scientifically robust and clinically meaningful NMA. …”
    Get full text
    Article
  2. 1682

    Is the topical application of sesame oil (Sesamum indicum L.) combined with standard care valuable and safe for managing infusion-related phlebitis: Evidence from a systematic review with meta-analysis of randomized controlled trials by Morteza Nasiri, Leila Amirmohseni, Mohammad Farzollah Abbasi, Fatemeh Yarahmadi, Sahar Zonoori, Mahya Torkaman, Elham Sadeghi Moghimi, Mehrnaz Ardaneh, Masoomeh Asadi

    Published 2025-03-01
    “…However, uncertainty remains because the evidence quality was moderate, some RCTs needed better methodological rigor, and most required to address the safety of the intervention or independent verification of SO used in terms of purity and potency. …”
    Get full text
    Article
  3. 1683
  4. 1684
  5. 1685
  6. 1686
  7. 1687
  8. 1688
  9. 1689
  10. 1690

    Large-scale evidence generation and evaluation across a network of databases for type 2 diabetes mellitus (LEGEND-T2DM): a protocol for a series of multinational, real-world comparative cardiovascular effectiveness and safety studies by Rohan Khera, Yuan Lu, Harlan M Krumholz, Martijn J Schuemie, Ruijun Chen, George Hripcsak, Marc A Suchard, Patrick B Ryan, Anna Ostropolets

    Published 2022-06-01
    “…Introduction Therapeutic options for type 2 diabetes mellitus (T2DM) have expanded over the last decade with the emergence of cardioprotective novel agents, but without such data for older drugs, leaving a critical gap in our understanding of the relative effects of T2DM agents on cardiovascular risk.Methods and analysis The large-scale evidence generations across a network of databases for T2DM (LEGEND-T2DM) initiative is a series of systematic, large-scale, multinational, real-world comparative cardiovascular effectiveness and safety studies of all four major second-line anti-hyperglycaemic agents, including sodium–glucose co-transporter-2 inhibitor, glucagon-like peptide-1 receptor agonist, dipeptidyl peptidase-4 inhibitor and sulfonylureas. …”
    Get full text
    Article
  11. 1691
  12. 1692
  13. 1693
  14. 1694
  15. 1695
  16. 1696
  17. 1697
  18. 1698
  19. 1699
  20. 1700